Table 2.
Legacy period (post-trial) rates of endpoint events and hazard ratios comparing randomized aspirin and placebo groups.
| Endpoint | Aspirin | Placebo | HR (95% CI) | P value | ||
|---|---|---|---|---|---|---|
| No. (%) of pts with event | Rate per 1000 py | No. (%) of pts with event | Rate per 1000 py | |||
|
| ||||||
| Primary endpoint* (N = 15,633) | 1088 (14ˑ0) | 34ˑ37 | 1083 (13ˑ8) | 33ˑ68 | 1ˑ02 (0ˑ94, 1ˑ11) | 0ˑ63 |
| Death | 448 (5ˑ8) | 14ˑ94 | 460 (5ˑ8) | 15ˑ07 | -- | -- |
| Dementia | 293 (3ˑ8) | 9ˑ99 | 287 (3ˑ6) | 9ˑ60 | -- | -- |
| Disability | 347 (4ˑ5) | 11ˑ75 | 336 (4ˑ3) | 11ˑ20 | -- | -- |
|
| ||||||
| Secondary endpoints † | ||||||
| Death (N = 16,357) | 822 (10ˑ2) | 23ˑ91 | 820 (9ˑ9) | 23ˑ35 | 1ˑ02 (0ˑ93, 1ˑ13) | 0ˑ62 |
| Dementia (N = 15,783) | 317 (4ˑ1) | 9ˑ96 | 314 (3ˑ9) | 9ˑ69 | 1ˑ03 (0ˑ88, 1ˑ20) | 0ˑ73 |
| Disability (N = 15,676) | 411 (5ˑ3) | 13ˑ11 | 409 (5ˑ2) | 12ˑ89 | 1ˑ02 (0ˑ89, 1ˑ17) | 0ˑ81 |
*
The first occurrence of any of the three components (death from any cause, dementia, or persistent physical disability). Participants not included if they experienced any of the three components during the RCT.
†
For the secondary endpoints, in addition to exclusions for non-consent and loss to follow-up, participants were excluded only if they experienced the specific event or death during the RCT.